Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib + CC-486 in accelerated phase myelofibrosis
DRKS00030348Phase 2Terminated
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Oct 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of fedratinib, CC-486 in myeloproliferative disorder (MPD), myelofibrosis (MF), sponsored by Martin Luther University Halle-Wittenberg. Started Oct 2022; status: terminated.
02
Drugs
fedratinibCC-486
03
Conditions
myeloproliferative disorder (MPD)myelofibrosis (MF)
Beyond the preview
Go deeper on DRKS00030348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00030348.